Trastuzumab News and Research

RSS

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.

4 Jun 2012

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.

4 Jun 2012

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint of a significant improvement in the time people with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival, PFS).

4 Jun 2012

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.

4 Jun 2012

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its division for research and diagnostic antibodies, AbD Serotec, will launch a series of novel anti-drug antibodies (ADAs) to strengthen its position as a leading provider of diagnostic reagents.

23 May 2012

CINJ prefers more personalized approach to prescribing cancer treatment

With recent advancements in technology and biomedical informatics, a more personalized approach to prescribing cancer treatment and developing these therapies is preferred over "one-size-fits-all" methods.

16 May 2012

Researchers identify new biomarker and therapeutic target for pancreatic cancer

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. The paper will be published May 15 in Cancer Research.

15 May 2012

Halozyme first quarter net loss increases to $15.1 million

Halozyme Therapeutics, Inc. today reported financial results for the quarter ended March 31, 2012.

8 May 2012

Leica receives FDA Pre-Market Approval for new HER2 IHC test

Leica Biosystems, a division of Leica Microsystems, announced that it has received Pre-Market Approval from the U.S. Food and Drug Administration for the Leica Bond Oracle HER2 IHC System with the Leica BOND-MAX, establishing their commitment to developing quality companion diagnostic products.

26 Apr 2012

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

9 Apr 2012

TGen to present TNBC study at AACR 2012 annual meeting

Because cases of Triple-Negative Breast Cancer (TNBC) are so genetically different, whole-genome sequencing is needed to detect the subtle molecular differences that might point to specific treatments for individual patients.

2 Apr 2012

Study identifies key mechanism behind breast cancer metastasis

A new study has identified a key mechanism that causes breast cancer to spread. The research, published by Cell Press on March 30th in the journal Molecular Cell, enhances our knowledge about the signals that drive cancer metastasis and identifies new therapeutic targets for a lethal form of invasive breast cancer that is notoriously resistant to treatment.

30 Mar 2012

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

ImmunoGen, Inc., a biotechnology company that develops anticancer products using its Targeted Antibody Payload (TAP) technology, today announced that Roche has announced positive topline results from its trastuzumab emtansine (T-DM1) EMILIA Phase III trial.

30 Mar 2012

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.

8 Feb 2012

Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment

Roche/Genentech/Chugai's pertuzumab plus trastuzumab (Roche/Genentech/Chugai's Herceptin) and docetaxel (Sanofi's Taxotere, generics) will become Decision Resources' proprietary clinical gold-standard treatment for metastatic first-line HER2-positive breast cancer in 2015.

3 Feb 2012

C&EN explains logic behind odd-sounding generic names

Oseltamivir. Esomeprazole. Trastuzumab. Where do drugs get those odd-sounding generic names? The answers are in the current issue of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, the world's largest scientific society, which explains the logic behind the tongue-twisters.

19 Jan 2012

Combination of lapatinib and trastuzumab more effective in treating HER2-positive breast cancer

Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent. In a report in the January 17 issue of The Lancet, an international research team reports that a protocol adding lapatinib (Tykerb) to trastuzumab (Herceptin) was more effective than single-drug treatment with either drug in eliminating microscopic signs of cancer at the time the tumors were surgically removed.

17 Jan 2012

Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types

Synta Pharmaceuticals Corp. Ganetespib shows potent in vitro and in vivo activity against multiple types of breast cancer including HER2-positive, ER/PR positive, triple-negative, and inflammatory breast cancer according to results presented at the San Antonio Breast Cancer Symposium.

13 Dec 2011

Trastuzumab improves long-term outcomes in obese patients with HER2-positive breast cancer

A large, multicenter, randomized study has shown that obese patients with HER2-positive breast cancer have larger tumors, increased lymph node involvement and, when not treated with trastuzumab, poorer long-term outcomes than normal-weight patients.

9 Dec 2011

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas.

9 Dec 2011

Trastuzumab News and Research

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

CINJ prefers more personalized approach to prescribing cancer treatment

Researchers identify new biomarker and therapeutic target for pancreatic cancer

Halozyme first quarter net loss increases to $15.1 million

Leica receives FDA Pre-Market Approval for new HER2 IHC test

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

TGen to present TNBC study at AACR 2012 annual meeting

Study identifies key mechanism behind breast cancer metastasis

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment

C&EN explains logic behind odd-sounding generic names

Combination of lapatinib and trastuzumab more effective in treating HER2-positive breast cancer

Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types

Trastuzumab improves long-term outcomes in obese patients with HER2-positive breast cancer

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News